Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Year range
1.
Ann Card Anaesth ; 2022 Jun; 25(2): 229-232
Article | IMSEAR | ID: sea-219217

ABSTRACT

Factor XII (FXII) deficiency is a congenital disorder inherited as an autosomal recessive condition. In his heterozygous form, it is relatively common in the general population. However, a total absence of FXII as seen in homozygous patients, is rare, with an incidence of approximately 1/1,000,000 individuals. Surprisingly, FXII deficiency is rather associated with thromboembolic complications. Patients do not experience a higher risk of surgical bleeding despite a markedly prolonged activated partial thromboplastin time. Given its low incidence in the general population, the finding of an unknown FXII deficiency is rare during cardiac surgery. This unique case describes a patient with an unanticipated prolonged baseline activated clotting time (ACT) during cardiac surgery in which his bleeding history and rotational thromboelastometry tracings lead us to the diagnosis of a FXII deficiency. The finding of a hypocoagulable INTEM tracing and a concurrent normal EXTEM tracing in a sample of a patient with prolonged ACT and adverse anamnestic bleeding history should prompt clinicians to consider a FXII deficiency. It may help clinicians in further perioperative management where there is not enough time to wait for the results of individual coagulation factor testing.

2.
Rev. cuba. pediatr ; 94(1)mar. 2022.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1409113

ABSTRACT

RESUMEN Introducción: El factor XII o factor de Hageman pertenece al sistema de contacto al ser iniciador de la vía intrínseca de la coagulación. Concentraciones bajas de este factor se asocian a tiempo de tromboplastina parcial activado prolongado, sin embargo, no se producen manifestaciones hemorrágicas como ocurre en la deficiencia de otros factores. Objetivo: Describir las manifestaciones clínicas de un lactante con diagnóstico de deficiencia de factor XII de la coagulación. Presentación del caso: Se presenta un lactante de 10 meses que tuvo aparición espontánea de equimosis y se diagnosticó un déficit de factor XII. Conclusiones: Aunque no es común, la deficiencia del factor XII puede estar asociada a manifestaciones hemorrágicas como equimosis tal como se describe en el presente caso.


ABSTRACT Introduction: Factor XII or Hageman factor belongs to the contact system as it is the initiator of the intrinsic coagulation pathway. Low concentrations of this factor are associated with prolonged activated partial thromboplastin time, however, hemorrhagic manifestations do not occur as occurs in the deficiency of other factors. Objective: Describe the clinical manifestations of an infant diagnosed with coagulation factor XII deficiency. Case presentation: A 10-month-old infant who had spontaneous onset of ecchymosis and a factor XII deficiency was diagnosed. Conclusions: Although not common, factor XII deficiency may be associated with hemorrhagic manifestations such as ecchymosis, as described in the present case.

3.
Malaysian Journal of Medicine and Health Sciences ; : 319-321, 2021.
Article in English | WPRIM | ID: wpr-979069

ABSTRACT

@#Factor XII deficiency, also known as the Hageman factor, is a rare disorder that has not been associated with any adverse outcomes. It is an interesting blood disorder whereby in the state of deficiency, it causes prolongation activated partial thromboplastin time (aPTT) which is correctable with mixing test. Although there have been case reports that have mentioned events of thrombosis and bleeding, however, no clear causal relationship has been established. Evidence for adverse events occurring in patients with Factor XII deficiency is sparse. We report here a case of a lady with a history of miscarriages who was incidentally found to have Factor XII deficiency during a routine workup for prolonged aPTT.

4.
Rev. chil. obstet. ginecol ; 77(1): 18-23, 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-627393

ABSTRACT

ANTECEDENTES: El déficit de factor XII es una enfermedad poco frecuente, relacionada con trombosis y abortos a repetición. OBJETIVO: Evaluar el resultado materno y perinatal en 25 embarazadas con déficit del factor XII. MÉTODOS: Estudio observacional descriptivo de 25 embarazadas (27 gestaciones) con esta patología desde enero 2005 a junio de 2011. RESULTADOS: La asociación de alteración del factor XII con otras trombofilias hereditarias o adquiridas es frecuente. En 24 mujeres se obtuvieron gestaciones exitosas, con sólo 3 abortos. Hubo 20 partos a término, con recién nacidos con peso y Apgar adecuado. Se registró un caso de restricción de crecimiento intrauterino. No hubo complicaciones médicas. Se utilizaron en todas las embarazadas antiagregantes y/o antitrombóticos como tratamiento. El fármaco utilizado más frecuente fue la heparina de bajo peso molecular, asociada en ocasiones al ácido acetilsalicílico. No hubo complicaciones por el uso de heparina de bajo peso molecular. CONCLUSIONES: El control multidisciplinar del embarazo y el tratamiento individualizado ha conseguido en esta patología buenos resultados maternos y neonatales.


BACKGROUND: The factor XII deficiency is a rare disease related with thrombosis and recurrent pregnancy loss. OBJECTIVE: To evaluate maternal and perinatal outcome in 25 pregnant women with deficiency of factor XII. METHODS: An observational descriptive study of 25 women with factor XII deficiency and pregnancy (27 pregnancies) between January 2005 and March 2011. RESULTS: The association with other inherited or acquired thrombophilia is common. 24 women have achieved successful pregnancies and only 3 miscarriages. There were 20 women with deliveries at term, with appropiate birth weight and Apgar test. There was one case of intrauterine growth restriction. There were no medical complications. The treatment used was antiplatelet and/or antithrombotic agents in all cases. The most used drug was low molecular weight heparin, sometimes associated to acetylsalicylic acid. CONCLUSIONS: A multidisciplinary control of the pregnancy and an individualized treatment has achieved good maternal and neonatal outcomes.


Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Factor XII Deficiency/drug therapy , Factor XII Deficiency/epidemiology , Pregnancy Complications, Hematologic , Prognosis , Thrombosis/etiology , Thrombosis/drug therapy , Birth Weight , Platelet Aggregation Inhibitors/therapeutic use , Pregnancy Outcome , Abortion, Spontaneous/etiology , Abortion, Spontaneous/epidemiology , Heparin, Low-Molecular-Weight/therapeutic use , Factor XII Deficiency/complications , Fibrinolytic Agents/therapeutic use , Anticoagulants/therapeutic use
5.
Korean Journal of Fertility and Sterility ; : 209-214, 2001.
Article in Korean | WPRIM | ID: wpr-160314

ABSTRACT

OBJECTIVE: To evaluate factor XII deficiency in patients with recurrent spontaneous abortion and its relation to aPTT. MATERIAL AND METHOD: Factor XII was analyzed by clotting method. RESULTS: Of 70 patients with recurrent spontaneous abortion, there were 35 cases of factor XII deficiency. Among them, there were only 3 cases of prolonged aPTT. CONCLUSIONS: It is still unclear whether factor XII deficiency is related to recurrent spontaneous abortion. Molecular approaches should be used to understand further the causal relationship. But based on this result, in the workup of patients with recurrent spontaneous abortion, factor XII should be included. aPTT is not likely to represent the abnormality of factor XII.


Subject(s)
Female , Humans , Pregnancy , Abortion, Spontaneous , Factor XII Deficiency , Factor XII
SELECTION OF CITATIONS
SEARCH DETAIL